Hanall Biopharma Co., Ltd.

A009420

KR7009420001

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 03:30:00 17/05/2024 am IST			5-day change	1st Jan Change
37,300 ^KRW	+2.05%		+9.87%	-15.80%

03/05	HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease	CI
06/03	Hanall Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Tranche Update on Hanall Biopharma Co.,Ltd's Equity Buyback Plan announced on March 10, 2022.

June 15, 2022 at 12:10 pm IST

From March 10, 2022 to June 10, 2022, the company has repurchased 519,451 shares, representing 1.01% for KRW 10,000.02 million. With this, the company has completed the repurchase of 519,451 shares, representing 1.01% for KRW 10,000.02 million under the buyback announced on March 10, 2022.

Latest news about Hanall Biopharma Co., Ltd.

HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease	03/05	CI
Hanall Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	06/03	CI
Vincere Biosciences Inc announced that it has received funding from Hanall Biopharma Co., Ltd., Daewoong pharmaceutical Co.,Ltd	12/23/12	CI
Hanall Biopharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
Interon Laboratories, Inc. announced that it has received funding from Hanall Biopharma Co., Ltd.	13/23/13	CI
Interon Laboratories, Inc. announced that it expects to receive funding from Hanall Biopharma Co., Ltd.	10/23/10	CI
HanAll's Licensed Partner in China Enters Sublicense Agreement with CSPC to Further Accelerate Development of Batoclimab	11/22/11	CI
Hanall's Second FcRn Inhibitor HL161ANS to Be Added to the Development Program of Its Licensed Partner	04/22/04	CI
Tranche Update on Hanall Biopharma Co.,Ltd's Equity Buyback Plan announced on March 10, 2022.	15/22/15	CI
Hanall Biopharma Co.,Ltd's Equity Buyback announced on March 10, 2022, has expired with 519,451 shares, representing 1.01% for KRW 10,000.02 million.	10/22/10	CI
Turn Biotechnologies, Inc. announced that it has received funding from Astellas Venture Management LLC, Daewoong pharmaceutical Co.,Ltd, Hanall Biopharma Co.,Ltd and other investors	12/22/12	CI
Hanall Biopharma Co.,Ltd announces an Equity Buyback for 543,479 shares.	10/22/10	CI
Hanall Biopharma Co.,Ltd authorizes a Buyback Plan.	10/22/10	CI
Alloplex Biotherapeutics, Inc. announced that it has received $1 million in funding from Daewoong pharmaceutical Co.,Ltd, Hanall Biopharma Co.,Ltd	19/21/19	CI
Hanall Biopharma Co.,Ltd Announces Consolidated Earnings Results for the Second Quarter and Six Months of 2021	29/21/29	CI
Hanall Biopharma Co.,Ltd Announces Earnings Results for the First Quarter Ended March 31, 2021	06/21/06	CI
HanAll Biopharma and Harbour Biomed Sign Collaboration and License Agreement for Development of Therapies in Greater China	12/17/12	CI
Biopharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate Vm202 for Non-Healing Diabetic Foot Ulcers	03/17/03	CI
HanAll Biopharma Co., Ltd.(KOSE:A009420) added to KOSPI 200 Index	10/16/10	CI
HanAll Biopharma Co., Ltd.(KOSE:A009420) added to MSCI Acwi + Frontier Markets(acwi Fm) All Cap Index	01/15/01	CI
HanAll Biopharma Co., Ltd.(KOSE:A009420) added to Russell Global Index	29/15/29	CI
Daewoong Pharmaceutical Co., Ltd. acquired 14.92% stake in HanAll Biopharma Co., Ltd. from Byung-Tae Kim, Sung-Soo Kim, Sung-Ji Kim, Dong-Shin Shin, and Hyun-Soo Kim for KRW 48 billion.	29/15/29	CI
Hanall Biopharma Co., Ltd. Announces Earnings Results for the First Half of Fiscal Year of 2014	26/14/26	CI
Kim Hong Cheol and two related parties acquired 5.3% stake in HanAll Biopharma Co., Ltd..	30/14/30	CI
HanAll Biopharma Co., Ltd.(KOSE:A009420) dropped from KOSPI 200 Index	17/14/17	CI

Chart Hanall Biopharma Co., Ltd.

Duration

Period

More charts

Company Profile

Hanall Biopharma Co Ltd is a Korea-based company principally engaged in the manufacture and distribution of synthetic pharmaceuticals and biopharmaceuticals. The Company mainly manufactures and sells pharmaceutical products including antidiabetic drugs, skin drugs, muscle relaxants, hepatitis drugs, digestion drugs, anti-cardiovascular drugs, neurologic drugs, interferons, antiviral drugs, antibiotics, antihistamine, anti-inflammatory drugs, and others. The Company also engages in the leasing of real estates. The Company distributes its products in domestic and overseas markets.

Sector

Pharmaceuticals

Calendar

14/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Hanall Biopharma Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

37,300 KRW

Average target price

43,600 KRW

Spread / Average Target

+16.89%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HANALL BIOPHARMA CO., LTD.	-15.80%	1.38B
ELI LILLY AND COMPANY	+32.09%	694B
NOVO NORDISK A/S	+29.39%	593B
JOHNSON & JOHNSON	-1.34%	371B
MERCK & CO., INC.	+20.34%	331B
ABBVIE INC.	+7.39%	290B
ASTRAZENECA PLC	+14.25%	239B
ROCHE HOLDING AG	-3.03%	209B
NOVARTIS AG	+10.02%	209B
AMGEN INC.	+8.49%	169B

Other Pharmaceuticals

Hanall Biopharma Co., Ltd.

Equities

A009420

KR7009420001

Pharmaceuticals

Tranche Update on Hanall Biopharma Co.,Ltd's Equity Buyback Plan announced on March 10, 2022.

Latest news about Hanall Biopharma Co., Ltd.

Chart Hanall Biopharma Co., Ltd.

Company Profile

Income Statement Evolution

Ratings for Hanall Biopharma Co., Ltd.

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals